Opyl (ASX:OPL) signed a service level agreement with Avion, a full-service contract research organization that delivers end-to-end clinical trial solutions, the company said in a Friday Australian bourse filing.
The partnership combines Avion's expertise in clinical trial management with Opyl's proprietary TrialKey platform, delivering data-driven insights to optimize trial design and improve outcomes, the filing said.
Under the agreement, Opyl and Avion will integrate Opyls's proprietary TrialKey platform into clinical trial planning and execution, and the company will provide Avion with reports and insights for AU$5,000 per report, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.